These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17226008)

  • 1. [Therapy with entecavir in chronic hepatitis B. BEHoLD-Study (Benefits of Entecavir for Hepatitis B Liver Disease)].
    Nitschman S; Erhardt A; Häussinger A
    Internist (Berl); 2007 Feb; 48(2):208-10. PubMed ID: 17226008
    [No Abstract]   [Full Text] [Related]  

  • 2. Entecavir.
    Opio CK; Lee WM; Kirkpatrick P
    Nat Rev Drug Discov; 2005 Jul; 4(7):535-6. PubMed ID: 16075486
    [No Abstract]   [Full Text] [Related]  

  • 3. [New advances in the treatment of chronic hepatitis B: position of entecavir].
    Olaso V
    Rev Esp Quimioter; 2007 Sep; 20(3):259-60. PubMed ID: 18080023
    [No Abstract]   [Full Text] [Related]  

  • 4. Successful Treatment of Hepatitis B Virus-associated Membranous Nephropathy with Entecavir and Immunosuppressive Agents.
    Ochi A; Ishimura E; Ichii M; Ohno Y; Nakatani S; Kobayashi I; Shima H; Tsuda A; Shidara K; Mori K; Tamori A; Inaba M
    Nephrology (Carlton); 2014 Sep; 19(9):595-6. PubMed ID: 25156438
    [No Abstract]   [Full Text] [Related]  

  • 5. Entecavir to treat severe acute hepatitis B.
    De Socio GV; Mercuri A; Di Candilo F; Baldelli F
    Scand J Infect Dis; 2009; 41(9):703-4. PubMed ID: 19544224
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only.
    Karlas T; Hartmann J; Weimann A; Maier M; Bartels M; Jonas S; Mössner J; Berg T; Tillmann HL; Wiegand J
    Transpl Infect Dis; 2011 Jun; 13(3):299-302. PubMed ID: 21159112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Entecavir therapy in a hepatitis B-related decompensated cirrhotic patient.
    Muneer B; Testa G; Millis JM; Mohanty SR
    South Med J; 2008 Nov; 101(11):1173-6. PubMed ID: 19088536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis B virus-related membranous nephropathy treated with entecavir.
    Ikee R; Ishioka K; Oka M; Maesato K; Moriya H; Hidaka S; Ohtake T; Kobayashi S
    Nephrology (Carlton); 2010 Mar; 15(2):266. PubMed ID: 20470290
    [No Abstract]   [Full Text] [Related]  

  • 9. Seroclearance of Hepatitis B surface antigen after entecavir treatment.
    Halichidis S; Dumea E; Cambrea CS
    J Gastrointestin Liver Dis; 2013 Jun; 22(2):236. PubMed ID: 23799228
    [No Abstract]   [Full Text] [Related]  

  • 10. A comparison of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive patients: a prospective cohort study in China.
    Zhang Y; Hu P; Qi X; Ren H; Mao RC; Zhang JM
    Clin Microbiol Infect; 2016 Mar; 22(3):287.e1-9. PubMed ID: 26548508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant.
    Jiménez-Pérez M; Sáez-Gómez AB; Mongil Poce L; Lozano-Rey JM; de la Cruz-Lombardo J; Rodrigo-López JM
    Transplant Proc; 2010 Oct; 42(8):3167-8. PubMed ID: 20970638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of entecavir for the treatment of complex forms of hepatitis B.
    Sacco R
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1333-43. PubMed ID: 24867511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Entecavir - options and obstacles of an effective treatment for chronic hepatitis B].
    Cornberg M; Manns MP
    Dtsch Med Wochenschr; 2010 Jan; 135(1-2):32-7. PubMed ID: 20024882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
    World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial.
    An J; Lim YS; Kim GA; Han SB; Jeong W; Lee D; Shim JH; Lee HC; Lee YS
    BMC Gastroenterol; 2017 Jan; 17(1):15. PubMed ID: 28103819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization.
    Yoo SH; Jang JW; Kwon JH; Jung SM; Jang B; Choi JY
    Clin Mol Hepatol; 2016 Dec; 22(4):458-465. PubMed ID: 28081589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early hepatitis B virological rebound on entecavir through selection of lamivudine-associated mutations.
    Tong CY; Mullen JE; Wong T
    J Antimicrob Chemother; 2009 Oct; 64(4):875-7. PubMed ID: 19671587
    [No Abstract]   [Full Text] [Related]  

  • 18. [Acute hepatitis B: is antiviral therapy indicated? Two case reports].
    Girke J; Wedemeyer H; Wiegand J; Manns MP; Tillmann HL
    Dtsch Med Wochenschr; 2008 May; 133(22):1178-82. PubMed ID: 18491273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: First-line monotherapies for chronic hepatitis B - indirect comparison between entecavir and tenofovir.
    Maratea D; Fadda V; Trippoli S; Messori A
    Aliment Pharmacol Ther; 2013 Mar; 37(5):584-5. PubMed ID: 23369168
    [No Abstract]   [Full Text] [Related]  

  • 20. New and emerging treatment of chronic hepatitis B.
    Keeffe EB; Marcellin P
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):285-94. PubMed ID: 17218162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.